Vasomotor Menopausal Symptoms (VMS) Treatment Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the vasomotor menopausal symptoms (vms) treatment market size evolved in recent years?
The vasomotor menopausal symptoms (VMS) treatment market has shown robust growth, set to expand from $17.86 billion in 2024 to $19.19 billion in 2025, with a 7.5% CAGR. Growth drivers include hormone replacement therapy (HRT), increased menopause awareness, pharmaceutical advancements, and rising consumer demand.
What are the predictions for the vasomotor menopausal symptoms (vms) treatment market size in the coming years?
The vasomotor menopausal symptoms (VMS) treatment market is forecasted to grow significantly, reaching $24.81 billion by 2029 at a CAGR of 6.6%. Growth drivers include advancements in personalized medicine, non-hormonal treatment innovations, dietary and nutritional interventions, and increased adoption of telemedicine and digital health solutions. Emerging trends include natural and alternative therapies, the rise of botanical and herbal remedies, menopause support groups, and the integration of cognitive behavioral therapy (CBT) into treatment strategies.
Get your vasomotor menopausal symptoms (vms) treatment market report here!
What key factors are fueling the growth of the vasomotor menopausal symptoms (vms) treatment market?
The rise in the population of women going through menopause is expected to enhance the growth of the vasomotor menopausal symptom’s treatment market. Menopause is a natural occurrence that demarcates the conclusion of a woman’s fertility period. Typically, it transpires between the ages of 45 and 55, with the median age being roughly 51. The growing population of women experiencing menopause, and the ensuing need for treatment to manage symptoms like hot flashes and vaginal dryness, is a major factor propelling the vasomotor menopausal symptoms (VMS) treatment market’s growth. As an example, the Cuyuna Regional Medical Center in the US projected in November 2022 that 1.1 billion women would be menopausal by 2025, as life expectancy for women increases. Furthermore, the menopausal population is predicted to grow by 1.6% each year till 2060. Hence, the rise in the menopause population is fostering the growth of the vasomotor menopausal symptom’s treatment market. Government initiatives to improve women’s health during menopause are expected to catalyze the growth of the vasomotor menopausal symptoms’ treatment market. These initiatives include funding for innovative studies on menopausal transition, preventing illnesses, and researching various pharmacological, clinical, and epidemiological elements of menopause. These actions are integrated parts of comprehensive women’s health programs. In January 2023, the Government of New South Wales, an agency in Australia, initiated a $40.3 million investment spanning four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs for women suffering from severe menopausal symptoms. Therefore, government initiatives geared towards improving women’s health during menopause are enhancing the growth of the vasomotor menopausal symptoms’ treatment market.
How is the global vasomotor menopausal symptoms (vms) treatment market divided into key segments?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
Who are the key firms paving the way for growth in the vasomotor menopausal symptoms (vms) treatment market?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
Which trends are expected to transform the vasomotor menopausal symptoms (vms) treatment market?
Key players in the treatment market for vasomotor menopausal symptoms are working on creating new treatments like Veozah, and securing necessary approvals to enhance treatment options and address the underserved medical needs in patients. The sanctioning of new medicines for menopause presents better efficiency and safety in relation to current treatments. For example, Astellas Pharma Inc, a pharmaceutical firm based in Japan, was granted approval by the Food and Drug Administration (FDA), a US federal unit, in May 2023 for Veozah (fezolinetant) 45 mg once daily for treating menopausal vasomotor symptoms (VMS), which can be mild to severe. This is the initial nonhormonal neurokinin 3 (NK3) receptor antagonist to be sanctioned for addressing VMS related to menopause. It is a hormone-free solution that impedes a brain pathway that aids in managing these symptoms, providing an alternative treatment for women dealing with these symptoms, particularly those who cannot or do not wish to use hormone therapy. The authorization of Veozah underscores its promise as a new medication for managing menopausal symptoms.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051
What regions are contributing significantly to the growth of the vasomotor menopausal symptoms (vms) treatment market?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Insulin Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2024
Smart Insulin Pens Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
